The effect of metformin on cardiovascular markers in female mice consuming a high fat diet. Issue 6 (November 2022)

• Record Type: Journal Article
• Authors: de Alwis, Natasha; Binder, Natalie K.; Mangwiro, Yeukai T.M.; Pritchard, Natasha; Beard, Sally; Kaitu'u-Lino, Tu'uhevaha J.; Brownfoot, Fiona; Hannan, Natalie J.
• Is Part Of: Obesity research & clinical practice. Volume 16:Issue 6(2022)
• Page Start: 524
• Page End: 532
• Publication Date: 2022-11
• Subjects: Obesity -- Metformin -- Cardiovascular disease; Obesity -- Research -- Periodicals; Obesity -- Treatment -- Periodicals; Obesity -- Periodicals; Obésité -- Recherche -- Périodiques; Obésité -- Traitement -- Périodiques; Obesity -- Research; Obesity -- Treatment; Electronic journals; Periodicals; 616.398
• DOI: 10.1016/j.orcp.2022.10.006
• Languages: English
• ISSNs: 1871-403X

Abstract

Abstract: Background: Metformin, widely used to treat diabetes, is now considered a candidate therapeutic for treatment of cardiovascular disease. This study aimed to assess whether metformin's non-glycaemic effects could mitigate cardiovascular disease indices in female mice consuming a high fat diet (HFD). Methods: Four-week old female Arc:Arc(S) mice were placed on a standard (std) chow diet or Western-style HFD (22% fat, 0.15% cholesterol). At ∼8 months, the mice were administered 150 mg/kg metformin or vehicle (control) via intraperitoneal injection for 11 days. Blood pressure was measured (tail cuff plethysmography) at Day 9 and 11 of treatment. On Day 11, mice were weighed and culled. The mesenteric arcade and kidneys were collected for assessment of vascular reactivity (wire myography), and assessment of expression of cardiometabolic markers (qPCR), respectively. Results: The HFD fed female mice were significantly heavier than those receiving the std diet at 1–12 weeks on diet, and at cull. Mice on a std diet with metformin treatment were significantly heavier at cull than the mice on a std diet administered the control treatment. Metformin treatment did not alter the weight of the mice receiving the HFD. Neither the HFD (compared to the std diet), nor metformin treatment (compared to control treatment) altered blood pressure, vascular reactivity, or expression of cardiometabolic markers in the kidney. Conclusion: Consumption of a Western-style HFD (without high salt/sugar levels) did not alter the cardiovascular markers measured. Further studies are required to establish the non-glycaemic, cardio-protective effects of metformin in high-risk cohorts. Highlights: A high fat diet causes significant, sustained increase in female mouse body weight. Exposure to metformin did not alter body weight of female mice on a high fat diet. Sustained high fat diet in female mice did not alter measured cardiovascular indices. Metformin did not alter measured cardiovascular indices in female mice.